Composition: 
Each coated tablet contains: Ibandronic acid (as monosodium Ibandronate monohydrate) 150 mg.

Therapeutic Action: 
Osteoclast bone resorption inhibition.

Posology: 
One 150 mg tablet once a month on the same date each month.

Presentations:
Containers containing 1, 2 and 3 tablets.